Filter Results:
(111)
Show Results For
- All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Show Results For
- All HBS Web
(111)
- News (22)
- Research (69)
- Events (1)
- Multimedia (3)
- Faculty Publications (48)
Page 1 of 111
Results →
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Merck
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry
Subramanian, Guhan, and Rhea Ghosh. "Remicade/Simponi: Confidential Instructions for Merck." Harvard Business School Exercise 911-044, May 2011. (Revised July 2012.)
George W. Merck
Merck played a pivotal role in the development of Merck & Company as a pharmaceutical research powerhouse. He created the firm’s first research division in 1933 and orchestrated the 1953 merger with... View Details
Keywords: Healthcare
- March 2001 (Revised September 2002)
- Case
Merck Latin America (A)
By: Michael Beer and James Weber
Introduces Grey Warner, the vice president of Merck's Latin America region, and his efforts to improve the organizational effectiveness of the region and to introduce a more global business culture and values. Discusses Merck's ethics and values, its Latin American... View Details
Keywords: Organizational Culture; Ethics; Business Processes; Strategic Planning; Change Management; Values and Beliefs; Globalized Firms and Management; Employee Relationship Management; Business Strategy; Government and Politics; Economy; Pharmaceutical Industry; Latin America
Beer, Michael, and James Weber. "Merck Latin America (A)." Harvard Business School Case 401-029, March 2001. (Revised September 2002.)
- September 1990 (Revised November 1991)
- Case
Merck & Co., Inc. (B)
In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major... View Details
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
- September 1990 (Revised November 1991)
- Case
Merck & Co., Inc. (A)
Merck & Co., Inc., a major pharmaceutical company, is in the process of reviewing and evaluating its personnel policies and practices. Employee interviews revealed that rewards for excellent performance were not adequate: outstanding performers received salary... View Details
Murphy, Kevin J. "Merck & Co., Inc. (A)." Harvard Business School Case 491-005, September 1990. (Revised November 1991.)
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- March 2001 (Revised September 2002)
- Case
Merck Latin America (D): Mexico
By: Michael Beer and James Weber
Examines Merck's change effort in Mexico from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Mexico
Beer, Michael, and James Weber. "Merck Latin America (D): Mexico." Harvard Business School Case 401-032, March 2001. (Revised September 2002.)
- January 2001
- Case
Merck Global Health Initiatives (A)
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Programs; Philanthropy and Charitable Giving; Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Pharmaceutical Industry; Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (A)." Harvard Business School Case 301-088, January 2001.
- January–February 1994
- Article
Financial Engineering at Merck
By: Timothy A. Luehrman
Luehrman, Timothy A. "Financial Engineering at Merck." Harvard Business Review 72, no. 1 (January–February 1994): 89–99.
- December 2018
- Case
Corporate Transformation at Merck KGaA, Darmstadt, Germany
By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
- June 1994 (Revised March 1995)
- Case
Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)
Kurt Landgraf, newly named CEO of Du Pont Merck Pharmaceutical Co., addresses complaints of discrimination from African-American scientists in R&D during significant downsizing and dramatic changes within the pharmaceutical industry. View Details
Keywords: Prejudice and Bias; Race Characteristics; Gender Characteristics; Diversity Characteristics; Conflict and Resolution; Pharmaceutical Industry
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)." Harvard Business School Case 394-202, June 1994. (Revised March 1995.)
- September 1990 (Revised November 1991)
- Supplement
Merck & Co., Inc. (C)
Discusses the 1989 modified performance appraisal program by adding performance gradations and allowing for differences in employee rating distributions depending on the division performance for the year. The objective is to have students discuss the revisions in the... View Details
Murphy, Kevin J. "Merck & Co., Inc. (C)." Harvard Business School Supplement 491-007, September 1990. (Revised November 1991.)
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Brazil
Beer, Michael, and James Weber. "Merck Latin America (C): Brazil." Harvard Business School Case 401-031, March 2001. (Revised September 2002.)
- March 2001 (Revised September 2002)
- Supplement
Merck Latin America (B): Argentina
By: Michael Beer and James Weber
Beer, Michael, and James Weber. "Merck Latin America (B): Argentina." Harvard Business School Supplement 401-030, March 2001. (Revised September 2002.)
- March 1999
- Case
Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)
By: Michael Beer and Perry Fagan
In the early 1990s, Merck faced a series of challenges because of significant changes in its competitive and regulatory environment (e.g., growth in power of pharmaceutical buyers like managed care organizations led to price pressures and President Clinton's review of... View Details
Keywords: Organizational Change and Adaptation; Business or Company Management; Organizational Culture; Problems and Challenges; Management Practices and Processes; Competitive Strategy; Management Teams; Health Care and Treatment; Governing Rules, Regulations, and Reforms; Situation or Environment; Alignment; Pharmaceutical Industry; United States
Beer, Michael, and Perry Fagan. "Merck & Co., Inc.: Corporate Strategy, Organization and Culture (A)." Harvard Business School Case 499-054, March 1999.
- April 2002
- Supplement
Grey Warner, Merck Latin America
By: Michael Beer
Grey Warner, the vice president of Merck's Latin America region, discusses the challenges raised in the case and the lessons learned. View Details
Keywords: Strategic Planning; Values and Beliefs; Change Management; Problems and Challenges; Management Teams; Pharmaceutical Industry; Latin America
Beer, Michael. "Grey Warner, Merck Latin America." Harvard Business School Video Supplement 402-801, April 2002.
- December 1997 (Revised September 1999)
- Supplement
Merck Sharp & Dohme Argentina, Inc. (B)
By: Lynn S. Paine and Hal Hogan
Supplements the (A) case. View Details
Paine, Lynn S., and Hal Hogan. "Merck Sharp & Dohme Argentina, Inc. (B)." Harvard Business School Supplement 398-034, December 1997. (Revised September 1999.)
- 09 Jun 2015
- News
How Merck Is Trying to Keep Disrupters at Bay
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Africa; Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
- 18 Mar 2020
- News